artificial intelligence Nov 14, 2022 MD Anderson Partners With Exscientia to Develop Precision Oncology Drugs Nov 10, 2022 Azra AI Partners With Massive Bio to Bring Clinical Trial Matching to its Platform Oct 31, 2022 Genomic Testing Cooperative Implementing AI, Molecular Profiling to Improve Cancer Diagnosis Premium Oct 26, 2022 HTG Molecular, OmiCure Partner to Use Transcriptome Panel to Guide Cancer Therapy Oct 19, 2022 Blue Earth Diagnostics, Siemens Healthineers Partner on Prostate Cancer Theranostics, PET Imaging Oct 7, 2022 Swiss Biotech PreComb Therapeutics Wants to Automate Functional Precision Medicine Premium Oct 5, 2022 Massive Bio, Perthera Partner on Biomarker-Based Clinical Trial Matching Sep 27, 2022 Optellum Raises $14M in Series A Financing Sep 7, 2022 Indivumed, CellPhenomics Partner on Cancer Drug Target Research Aug 31, 2022 Syapse, Genesis Research Partner to Offer Expanded Oncology Real-World Evidence Services Aug 11, 2022 Clarified Precision Medicine, VieCure Partner to Make Precision Oncology Expertise More Accessible Aug 2, 2022 Envisagenics Wins $2M SBIR Grant From NCI for Splicing-Based Immunotherapy Target Discovery Platform Jul 11, 2022 HER2-Low Response Data Spurs Paige to Develop New Breast Cancer Pathology Test Premium Jun 14, 2022 Digital Pathology Firm Proscia Raises $37M in Series C Round Jun 9, 2022 Sophia Genetics, GE Healthcare Begin DEEP-Lung-IV Data Collection, Technology Integration Premium May 9, 2022 AI-Based CT Imaging Model Could Catch Pancreatic Cancer Early Premium Apr 28, 2022 Owkin, ADC Therapeutics Team on AI-Based Biomarker Discovery Apr 28, 2022 LifeOmic Partners With xCures to Speed Search for Treatments in Patient Medical Records Apr 27, 2022 Lunit Gets CE Mark for AI-Based PD-L1 Expression Test Apr 26, 2022 Valar Labs Using $4M in Seed Financing to Advance AI Tool for Personalizing Cancer Treatment Premium Load More Breaking News Marengo Therapeutics Begins Phase I/II Trial of Selective T-Cell-Targeted Antibody Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial In Brief This Week: PreludeDx, Johnson & Johnson, Syros, Magenta, Merck NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer
